GTx GTXI

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Nvidia, Android, And Opportunity

      Headlines

      Mon, 30 Jun 2014

      in stock price, eyes have been on Nvidia ( NVDA ) and its actions revolving the expansion of its GPU business. With GeForce GTX revenues up over 50% from the beginning of the year, there has been little doubt that the company can maintain its dominance

    2. When Flexibility Meets Opportunity in the European Commercial Real Estate Market

      Headlines

      Wed, 13 Nov 2013

      We are raising GTx 's fair value on recent positive Phase II trial results for Ostarine.

    3. America: The New Europe?

      Headlines

      Wed, 2 Oct 2013

      GTx adds a European partner.

    4. GTx muscle drug fails late-stage trials, shares plunge

      Headlines

      Mon, 19 Aug 2013

      (Reuters) - GTx Inc's experimental drug to treat muscle wasting in cancer patients became its second successive lead drug to fail late-stage trials, wiping out nearly two-thirds of the market value...

    5. Dropping Coverage of GTx

      Commentary

      Sun, 24 Oct 2010

      We're dropping coverage of GTx Inc GTXI to focus our resources elsewhere.

    6. Drug Development Moves Along at GTx

      Commentary

      Fri, 17 Sep 2010

      GTx Inc. GTXI reported second-quarter results that came ..... treatment for advanced prostate cancer, GTx -758, met endpoints in a Phase II study ..... Administration, and will continue to push ahead on GTx 758. In the meantime, GTx continues to

    7. New Morningstar Analyst Report - GTx , Inc.

      Stock Reports

      Wed, 9 Jun 2010

      generate substantial revenue . Acapodene is GTx 's first in - house drug candidate . The ..... traction with urologists or oncologists . GTx may not have success in repartnering Ostarine ..... large potential patient population . If GTx can establish another partnership or independently

    8. Disappointing Results for GTx

      Commentary

      Wed, 26 May 2010

      GTx GTXI reported disappointing results in its Phase III trial for Acapodene for the ..... study protocol and demands a larger or more expensive trial that rises above GTx and partner Ipsen's preset funding threshold for a second trial . Then the

    9. GTx , Ipsen Expand Deal

      Commentary

      Tue, 23 Mar 2010

      GTx GTXI announced Tuesday that it has expanded its deal with European partner Ipsen . Ipsen will pay GTx about $ 58 million in milestones for a second ..... European approval . This deal will improve GTx 's near - term cash reserves and help it

    10. GTx under Review

      Commentary

      Wed, 3 Mar 2010

      We are placing GTx GTXI under review until the firm reports earnings ..... of the Ostarine (MK-2866) compound. GTx partnered with Merck MRK on this compound ..... currently discussing next steps with GTx ." Ostarine drives the lion's share

    « Prev123Next »
    Content Partners